---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-007951"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:54:08.084641+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Immuneering Q1 net loss $12.9M; reiterates FY2022 opex $55-60M; IMM-1-104 IND on track for Q3 2022

## Summary
- Net loss $12.9M ($0.49/share) vs $6.2M ($1.26/share) in Q1 2021; R&D $9.1M, G&A $4.0M.
- Cash $137.8M as of March 31, 2022; cash runway into Q3 2024.
- IMM-1-104 IND filing expected Q3 2022; first patient enrollment Phase 1 expected Q4 2022.
- IMM-6-415 IND filing expected 2023.
- FY2022 GAAP opex guidance $55-60M including non-cash stock-based comp.

## SEC filing metadata
- accession: 0001558370-22-007951
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000155837022007951/0001558370-22-007951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000155837022007951/imrx-20220510x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-007951
- JSON: https://secwatch.observer/filing/0001558370-22-007951.json
- Plain text: https://secwatch.observer/filing/0001558370-22-007951.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.